Search Result

Results for "

peripherally active

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Adrenergic Receptor (7) Aldose Reductase (1) Amyloid-β (2) Angiotensin Receptor (2) Angiotensin-converting Enzyme (ACE) (4) Apoptosis (7) Autophagy (8) Beta-secretase (1) Calcium Channel (9) Cannabinoid Receptor (3) Caspase (4) Cholinesterase (ChE) (3) COMT (6) Dopamine Receptor (6) Endogenous Metabolite (3) FAAH (1) Formyl Peptide Receptor (FPR) (1) Histamine Receptor (5) HIV (3) Isotope-Labeled Compounds (5) LPL Receptor (2) MAGL (1) MMP (2) Monocarboxylate Transporter (1) NF-κB (1) Opioid Receptor (5) P2Y Receptor (3) PGE synthase (1) Phosphodiesterase (PDE) (3) Potassium Channel (3) Reactive Oxygen Species (5) SARS-CoV (6) Sodium Channel (6)
By Research Areas:	Cancer (14) Cardiovascular Disease (31) Endocrinology (11) Infection (2) Inflammation/Immunology (15) Metabolic Disease (7) Neurological Disease (35)

By Targets:

5-HT Receptor (2)

Adrenergic Receptor (7)

Aldose Reductase (1)

Amyloid-β (2)

Angiotensin Receptor (2)

Angiotensin-converting Enzyme (ACE) (4)

Apoptosis (7)

Autophagy (8)

Beta-secretase (1)

Calcium Channel (9)

Cannabinoid Receptor (3)

Caspase (4)

Cholinesterase (ChE) (3)

COMT (6)

Dopamine Receptor (6)

Endogenous Metabolite (3)

FAAH (1)

Formyl Peptide Receptor (FPR) (1)

Histamine Receptor (5)

HIV (3)

Isotope-Labeled Compounds (5)

LPL Receptor (2)

MAGL (1)

MMP (2)

Monocarboxylate Transporter (1)

NF-κB (1)

Opioid Receptor (5)

P2Y Receptor (3)

PGE synthase (1)

Phosphodiesterase (PDE) (3)

Potassium Channel (3)

Reactive Oxygen Species (5)

SARS-CoV (6)

Sodium Channel (6)

By Research Areas:

Cancer (14)

Cardiovascular Disease (31)

Endocrinology (11)

Infection (2)

Inflammation/Immunology (15)

Metabolic Disease (7)

Neurological Disease (35)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106538

Cadralazine

ISF 2469
Others Cardiovascular Disease

Cadralazine (ISF 2469) is an orally active antihypertensive agent. Cadralazine is a peripheral arteriolar vasodilator .

Cadralazine ISF 2469	Others	Cardiovascular Disease
Cadralazine (ISF 2469) is an orally active antihypertensive agent. Cadralazine is a peripheral arteriolar vasodilator .

HY-116239

Zenarestat	Aldose Reductase	Neurological Disease Metabolic Disease
Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats .

HY-B0233

Isradipine PN 200-110	Calcium Channel Autophagy	Cardiovascular Disease Neurological Disease
Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease .

HY-110206

AM6545	Cannabinoid Receptor	Metabolic Disease
AM6545 is a peripherally active, cannabinoid receptor antagonist with limited brain penetration. AM6545 binds to CB1 and CB2 receptors with K_is of 1.7 nM and 523 nM, respectively. AM6545 is a neutral antagonist. AM6545 can be used for the research of obesity and its complications .

HY-157527

hAChE-IN-7	Cholinesterase (ChE) Beta-secretase	Neurological Disease
hAChE-IN-7 (compound 5s) is a mixed inhibitor affecting both the catalytic active site (CAS) and peripheral anionic site (PAS) of hAChE. hAChE-IN-7 displays the balanced inhibitory effect on hAChE (IC₅₀=69.8 nM) and hBuChE (IC₅₀=68.0 nM), and exhibits inhibitory activity against β-secretase-1 (BACE-1) (IC₅₀=3.6 μM). hAChE-IN-7 has the potential for Alzheimer's disease (AD) research .

HY-B1895

Levodropropizine (S)-(-)-Dropropizine; DF-526	Histamine Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Levodropropizine (DF-526) is an orally active histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive agent .

HY-119605

DAA-1097

Others Neurological Disease

DAA-1097 is an orally active and selective agonist for the peripheral benzodiazepine receptor (PBR). DAA-1097 has anxiolytic effects .

DAA-1097	Others	Neurological Disease
DAA-1097 is an orally active and selective agonist for the peripheral benzodiazepine receptor (PBR). DAA-1097 has anxiolytic effects .

HY-105266

Zabicipril	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Zabicipril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Zabicipril can be used for the study of blood pressure and peripheral arterial insufficiency .

HY-107384

Asimadoline EMD-61753	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Asimadoline (EMD-61753) is an orally active, selective and peripherally active κ-opioid agonist with IC₅₀s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .

HY-107384A

Asimadoline hydrochloride EMD-61753 hydrochloride	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Asimadoline (EMD-61753) hydrochloride is an orally active, selective and peripherally active κ-opioid agonist with IC₅₀s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline hydrochloride has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline hydrochloride ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .

HY-B0233S1

Isradipine-d6 PN 200-110-d₆	Calcium Channel Autophagy
Isradipine-d₆ is the deuterium labeled Isradipine[1]. Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease[2][3][4].

HY-B0233S2

Isradipine-d7 PN 200-110-d₇	Calcium Channel Autophagy Isotope-Labeled Compounds	Cardiovascular Disease Neurological Disease
Isradipine-d₇ is deuterated labeled Isradipine (HY-B0233). Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease .

HY-B0233R

Isradipine (Standard)	Calcium Channel Autophagy	Cardiovascular Disease Neurological Disease
Isradipine (Standard) is the analytical standard of Isradipine. This product is intended for research and analytical applications. Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease .

HY-106147

Frakefamide	Opioid Receptor	Neurological Disease
Frakefamide is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system .

HY-15283

Clopidogrel 15+ Cited Publications Clopidogrelum	P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

HY-106147B

Frakefamide TFA	Opioid Receptor	Neurological Disease
Frakefamide TFA is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system .

HY-129787

PF-03550096	Cannabinoid Receptor	Neurological Disease
PF-03550096 is an orally active synthetic cannabinoid (CB) that selectively targets peripheral CB2 receptors with a K_i value of 7.9 nM. PF-03550096 has analgesic activity .

HY-B0233S

Isradipine-d3	Calcium Channel Autophagy	Cardiovascular Disease Neurological Disease
Isradipine-d₃ (PN 200-110-d3) is the deuterium labeled Isradipine. Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease[1][2][3].

HY-B0259

Indapamide	Potassium Channel	Cardiovascular Disease
Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .

HY-116477

URB937	FAAH	Neurological Disease Inflammation/Immunology
URB937 is an orally active and peripherally restricted FAAH inhibitor (IC₅₀=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier) .

HY-B0484A

Buflomedil	Others	Cardiovascular Disease
Buflomedil is an orally active vasoactive agent. Buflomedil is an α1-, α2-adrenolytic compound. Buflomedil can be used for research of cardiovascular disease, such as peripheral vascular disease .

HY-B1895R

Levodropropizine (Standard)	Histamine Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Levodropropizine (Standard) is the analytical standard of Levodropropizine. This product is intended for research and analytical applications. Levodropropizine (DF-526) is an orally active histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive agent .

HY-B0347

Lacidipine 1 Publications Verification	Calcium Channel Reactive Oxygen Species Caspase Apoptosis	Cardiovascular Disease
Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI) .

HY-125881

ASP1126	LPL Receptor	Inflammation/Immunology
ASP1126 is a selective and orally active sphingosine-1-phosphate (S1P) agonist, with EC₅₀ values of 7.12 nM, 517 nM for hS1P₁ and hS1P₃, respectively. ASP1126 decreases the number of peripheral lymphocytes, naive T cells, central memory T cells and effector memory T cells in the peripheral blood. ASP1126 has the potential to be applied in clinical transplantation with improved safety profile .

HY-112707

AM9405	Cannabinoid Receptor 5-HT Receptor	Neurological Disease
AM9405 is a novel peripherally active cannabinoid type 1 (CB1) and serotonin type 3 receptor agonist. AM9405 inhibits twitch contraction of the ileum and the colon with IC₅₀s of 45.71 and 0.076 nM, respectively.

HY-118284

Vicagrel 1 Publications Verification	P2Y Receptor	Cardiovascular Disease
Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .

HY-108353

Isoprenaline	Adrenergic Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Isoprenaline is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma .

HY-B0468

Isoprenaline hydrochloride Maximum Cited Publications 47 Publications Verification Isoproterenol hydrochloride	Adrenergic Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Isoprenaline (Isoproterenol) hydrochloride is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma .

HY-N7514

Strictosidinic acid	5-HT Receptor	Neurological Disease
Strictosidinic acid, an orally active glycoside indole monoterpene alkaloid isolated from Psychotria myriantha leaves, inhibits precursor enzymes of 5-HT biosynthesis and reduces the 5-HT levels. Strictosidinic acid has peripheral analgesic and antipyretic activities in mice .

HY-108353A

Isoprenaline hemisulfate	Adrenergic Receptor Endogenous Metabolite	Cardiovascular Disease Endocrinology
Isoprenaline hemisulfate is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma .

HY-N12141

Flaccidoside II	Apoptosis	Inflammation/Immunology
Flaccidoside II inhibits proliferation and induces apoptosis in Malignant peripheral nerve sheath tumors (MPNSTs) cell lines. Flaccidoside II ameliorates collagen-induced arthritis in mice. Flaccidoside II is an active triterpenoid saponin constituent from Anemone flaccida rhizome .

HY-B0259S

(rac)-Indapamide-d3	Potassium Channel	Cardiovascular Disease
(rac)-Indapamide-d₃ is a labelled racemic Indapamide. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy[1][4].

HY-15283R

Clopidogrel (Standard)	P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel (Standard) is the analytical standard of Clopidogrel. This product is intended for research and analytical applications. Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

HY-B0347S1

Lacidipine-13C8	Apoptosis Caspase Calcium Channel Reactive Oxygen Species	Cardiovascular Disease
Lacidipine- ¹³C₈ is the deuterium labeled Lacidipine[1]. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI)[2][3].

HY-B0347S3

Lacidipine-13C4	Calcium Channel Caspase Reactive Oxygen Species Apoptosis Isotope-Labeled Compounds	Cardiovascular Disease
Lacidipine- ¹³C₄ is ¹³C labeled Lacidipine (HY-B0347). Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI) .

HY-B0347R

Lacidipine (Standard)	Calcium Channel Reactive Oxygen Species Caspase Apoptosis	Cardiovascular Disease
Lacidipine (Standard) is the analytical standard of Lacidipine. This product is intended for research and analytical applications. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI) .

HY-17034

Medetomidine	Adrenergic Receptor	Neurological Disease Endocrinology
Medetomidine is an orally active α2-adrenoceptor agonist (K_i: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-17034B

Medetomidine hydrochloride MPV785	Adrenergic Receptor	Neurological Disease Endocrinology
Medetomidine hydrochloride is an orally active α2-adrenoceptor agonist (K_i: 1.08 nM). Medetomidine hydrochloride has sedative and analgesic effects. Medetomidine hydrochloride can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .

HY-N6857

Armepavine	NF-κB	Inflammation/Immunology
Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades .

HY-B0259R

Indapamide (Standard)	Potassium Channel	Cardiovascular Disease
Indapamide (Standard) is the analytical standard of Indapamide. This product is intended for research and analytical applications. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .

HY-B0362A

Phentolamine mesylate 3 Publications Verification Phentolamine methanesulfonate	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Phentolamine mesylate (Phentolamine methanesulfonate) is a reversible, non-selective, and orally active blocker of α1 and α2 adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance. Phentolamine mesylate can be used for the research of pheochromocytoma-related hypertension, heart failure and erectile dysfunction .

HY-B0164

Mizolastine	Histamine Receptor	Inflammation/Immunology
Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial .

HY-B0164A

Mizolastine dihydrochloride	Histamine Receptor	Inflammation/Immunology
Mizolastine dihydrochloride is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine dihydrochloride effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine dihydrochloride can be used in studies of allergic rhinitis and chronic idiopathic urticarial .

HY-18977

KML29 2 Publications Verification	MAGL	Metabolic Disease Inflammation/Immunology
KML29 is an extremely selective, orally active and irreversible MAGL inhibitor, with IC₅₀ values of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively. KML29 exhibits minimal cross-reactivity toward other central and peripheral serine hydrolases, including no detectable activity against FAAH .

HY-127026S

Quinaprilat-d5	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Quinaprilat-d₅ is a deuterium-labeled Quinaprilat. Quinaprilat is a nonsulfhydryl ACE inhibitor, the active diacid metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits bradykinin degradation. Quinaprilat primarily acts as a vasodilator, decreasing total peripheral and renal vascular resistance[1].

HY-N4115

Syrosingopine 4 Publications Verification Su 3118	Monocarboxylate Transporter	Cardiovascular Disease Cancer
Syrosingopine (Su 3118) is an orally active lactate transporters (MCT1/MCT4) dual inhibitor, which can reduce glycolysis and induce synthetic lethality in cancer cells when combine with metformin. Syrosingopine shows anti-hypertensive activity by depleting peripheral stores of norepinephrine .

HY-B0464A

Hydralazine	Reactive Oxygen Species	Cardiovascular Disease Inflammation/Immunology
Hydralazine is a orally active antihypertensive agent, reduces peripheral resistance directly by relaxing the smooth muscle cell layer in arterial vessel. Hydralazine has antioxidant activity, as well as inhibits reactive oxygen species (ROS) release and O₂ ^·- generation with an IC₅₀ value of 9.53 mM and 1.19 mM, respectively .

HY-17406

Tolcapone 1 Publications Verification Ro 40-7592	COMT Amyloid-β Apoptosis	Neurological Disease Cancer
Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC₅₀ of 773 nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .

HY-144126

S1P1 agonist 5	LPL Receptor	Inflammation/Immunology
S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS) .

HY-N3931

Gardneramine	Others	Cardiovascular Disease
Gardneramine is an orally active alkaloid that acts like papaverine. Gardneramine has peripheral vascular diastolic effect, direct inhibition on myocardium and central inhibition. Gardneramine showed antihypertensive, vasodilatation and atrial inhibition effects in rabbit, dog and guinea pig models, respectively. Gardneramine also inhibits the movement of smooth muscle organs such as the stomach and intestines .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0468

Isoprenaline hydrochloride Maximum Cited Publications 47 Publications Verification Isoproterenol hydrochloride	Cardiovascular Disease Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields Endocrinology	Adrenergic Receptor Endogenous Metabolite
Isoprenaline (Isoproterenol) hydrochloride is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma .

HY-108353

Isoprenaline	Cardiovascular Disease Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields Endocrinology	Adrenergic Receptor Endogenous Metabolite
Isoprenaline is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma .

HY-N7514

Strictosidinic acid	Alkaloids other families Source classification Plants Indole Alkaloids	5-HT Receptor
Strictosidinic acid, an orally active glycoside indole monoterpene alkaloid isolated from Psychotria myriantha leaves, inhibits precursor enzymes of 5-HT biosynthesis and reduces the 5-HT levels. Strictosidinic acid has peripheral analgesic and antipyretic activities in mice .

HY-108353A

Isoprenaline hemisulfate	Cardiovascular Disease Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields Endocrinology	Adrenergic Receptor Endogenous Metabolite
Isoprenaline hemisulfate is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma .

HY-N12141

Flaccidoside II	Structural Classification Polysaccharides Anemone flaccida Fr. Schmidt Source classification Ranunculaceae Plants Saccharides	Apoptosis
Flaccidoside II inhibits proliferation and induces apoptosis in Malignant peripheral nerve sheath tumors (MPNSTs) cell lines. Flaccidoside II ameliorates collagen-induced arthritis in mice. Flaccidoside II is an active triterpenoid saponin constituent from Anemone flaccida rhizome .

HY-N6857

Armepavine	Alkaloids Monophenols other families Classification of Application Fields Source classification Phenols Nelumbo nucifera Gaertn. Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Nymphaeaceae	NF-κB
Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades .

HY-N3931

Gardneramine	Structural Classification Alkaloids Nepenthes mirabilis (Lour.) Druce Source classification Plants Nepenthaceae	Others
Gardneramine is an orally active alkaloid that acts like papaverine. Gardneramine has peripheral vascular diastolic effect, direct inhibition on myocardium and central inhibition. Gardneramine showed antihypertensive, vasodilatation and atrial inhibition effects in rabbit, dog and guinea pig models, respectively. Gardneramine also inhibits the movement of smooth muscle organs such as the stomach and intestines .

HY-B0715

Pentoxifylline 5+ Cited Publications BL-191; PTX; Oxpentifylline	Classification of Application Fields Disease Research Fields Cancer	Phosphodiesterase (PDE) Autophagy HIV
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

Cat. No.	Product Name	Chemical Structure

HY-B0233S1

Isradipine-d6
Isradipine-d₆ is the deuterium labeled Isradipine[1]. Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease[2][3][4].

HY-B0233S2

Isradipine-d7
Isradipine-d₇ is deuterated labeled Isradipine (HY-B0233). Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease .

HY-B0233S

Isradipine-d3

Isradipine-d₃ (PN 200-110-d3) is the deuterium labeled Isradipine. Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease[1][2][3].

HY-B0259S

(rac)-Indapamide-d3
(rac)-Indapamide-d₃ is a labelled racemic Indapamide. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy[1][4].

HY-B0347S1

Lacidipine-13C8

Lacidipine- ¹³C₈ is the deuterium labeled Lacidipine[1]. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI)[2][3].

HY-B0347S3

Lacidipine-13C4

Lacidipine- ¹³C₄ is ¹³C labeled Lacidipine (HY-B0347). Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI) .

HY-127026S

Quinaprilat-d5
Quinaprilat-d₅ is a deuterium-labeled Quinaprilat. Quinaprilat is a nonsulfhydryl ACE inhibitor, the active diacid metabolite of Quinapril. Quinaprilat specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits bradykinin degradation. Quinaprilat primarily acts as a vasodilator, decreasing total peripheral and renal vascular resistance[1].

HY-12717AS

Phentolamine-d4 hydrochloride

Phentolamine-d₄ (hydrochloride) is the deuterium labeled Phentolamine hydrochloride. Phentolamine hydrochloride is a reversible, non-selective, and orally active blocker of α1 and α2 adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance. Phentolamine hydrochloride can be used for the research of pheochromocytoma-related hypertension, heart failure and erectile dysfunction[1][2][3].

HY-B0715S

Pentoxifylline-d6

Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-17406S1

Tolcapone-d4

Tolcapone-d₄ is the deuterium labeled Tolcapone. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver[1]. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis[2]. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma[3].

HY-B0715S2

Pentoxifylline-d5

Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-119980S

Fluphenazine-d8

Fluphenazine-d₈ is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .

HY-14280S

Entacapone-d10

Entacapone-d₁₀ is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks